|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Antibody | Rituximab | Obinutuzumab | Ofatumumab | Ocrelizumab |
| Structure | Chimeric | Glycoengineered Humanized | Fully human | Humanized |
| Route | IV | IV | SQ | IV |
| Primary MOA | CDC > ADCC | ADCC > CDC | CDC > ADCC | ADCC > CDC |
| Side Effects | Infusion reactions, infections, hypogammaglobulinemia, neutropenia |

**Supplementary Table 1. Overview of anti-CD20 monoclonal antibodies with reported use in IIM**

**Supplementary Table 1. Overview of anti-CD20 monoclonal antibodies with reported use in IIM.** IV: Intravenous; SQ: subcutaneous; CDC: complement-dependent cytotoxicity; ADCC: antibody-dependent cellular cytotoxicity